CHILDRENS CANCER GROUP
儿童癌症组
基本信息
- 批准号:6124403
- 负责人:
- 金额:$ 29.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1976
- 资助国家:美国
- 起止时间:1976-12-01 至 2002-11-30
- 项目状态:已结题
- 来源:
- 关键词:acute lymphocytic leukemia acute myelogenous leukemia antineoplastics bone marrow transplantation bone neoplasms brain neoplasms clinical research clinical trials combination cancer therapy combination chemotherapy cooperative study cytogenetics data management human subject human therapy evaluation liver neoplasms lymphoma molecular oncology neoplasm /cancer chemotherapy neoplasm /cancer diagnosis neoplasm /cancer epidemiology neoplasm /cancer immunotherapy neoplasm /cancer pharmacology neoplasm /cancer radiation therapy neoplasm /cancer surgery neuroblastoma oncology nursing pediatric neoplasm /cancer statistics /biometry tissue resource /registry
项目摘要
Dramatic gains have been made in childhood cancer including markedly more effective therapy, insights into the biology of these diseases, a clearer definition of etiologic factors, and a new focus on the outcomes of the survivors of these diseases. These gains have largely been facilitated by the cooperative clinical trials groups. This grant will facilitate the continued involvement of the investigators at the University of Minnesota in the multi-institutional cooperative therapeutic and non- therapeutic studies conducted by the Children's Cancer Group (CCG). Minnesota investigators have been at the forefront of all of these venues over the past grant cycle and are poised to continue this productive relationship into the future. In 1997, the Minnesota consortium registered 162 patients on therapeutic trials (phase I, II, and III) and, in addition, registered patients on almost 100 non-therapeutic (biology, epidemiology) studies. The combination of strong patient accrual, data management, group leadership, and authorship of CCG publications resulted in Minnesota being ranked first among all group institutions in 1995, 1996, and 1997. Minnesota investigators have continued strong leadership roles in Epidemiology and Cancer Control, Hematopoetic Stem Cell Transplantation, acute lymphoblastic and acute myeloid leukemia, biology, and experimental therapeutics. Over the past grant cycle, Minnesota investigators have chaired fourteen group therapeutic or scientific committees and served as vice-chairs on an additional twenty four. Minnesota has consistently led the group in first- authorship of group publications. Institutional research in stem cell transplantation, epidemiology and cancer control, experimental therapeutics, and biology has been applied to group studies and future investigations of all of these areas are under development. This grant requests support for the personnel critical to our future group activities. It will assure continued excellence in data management, allow travel by investigators and other key personnel to group meetings, and supply the funds needed for expenses generated by the accrual of patients to group studies. This funding will assure the continued leadership of Minnesota investigators in all aspects of the Children's Cancer Group over the coming five years.
在儿童癌症方面取得了巨大的进展,包括显着更有效的治疗、对这些疾病的生物学的深入了解、对病因因素的更清晰的定义以及对这些疾病幸存者的结果的新关注。这些成果很大程度上是由临床试验合作小组推动的。 这笔赠款将促进明尼苏达大学的研究人员继续参与儿童癌症小组 (CCG) 进行的多机构合作治疗和非治疗研究。 在过去的资助周期中,明尼苏达州的调查人员一直处于所有这些场所的最前沿,并准备在未来继续这种富有成效的关系。 1997 年,明尼苏达联盟登记了 162 名患者进行治疗试验(I、II 和 III 期),此外,还登记了近 100 项非治疗(生物学、流行病学)研究的患者。 强大的患者应计、数据管理、小组领导和 CCG 出版物作者的结合使明尼苏达州在 1995 年、1996 年和 1997 年在所有小组机构中排名第一。明尼苏达州的研究人员在流行病学和癌症控制、造血干细胞移植、急性淋巴细胞和急性髓细胞白血病、生物学和实验治疗学方面继续发挥着强有力的领导作用。 在过去的拨款周期中,明尼苏达州的研究人员担任了 14 个团体治疗或科学委员会的主席,并在另外 24 个委员会中担任副主席。 明尼苏达州在团体出版物的第一作者方面一直处于领先地位。 干细胞移植、流行病学和癌症控制、实验治疗和生物学方面的机构研究已应用于团体研究,所有这些领域的未来研究都在开发中。 这笔赠款要求为对我们未来团体活动至关重要的人员提供支持。 它将确保数据管理的持续卓越性,允许研究人员和其他关键人员出差参加小组会议,并提供小组研究患者应计产生的费用所需的资金。 这笔资金将确保明尼苏达州研究人员在未来五年内继续在儿童癌症小组的各个方面发挥领导作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joseph P Neglia其他文献
Contributions of cancer treatment and genetic predisposition to risk of subsequent neoplasms in long-term survivors of childhood cancer: a report from the St Jude Lifetime Cohort and the Childhood Cancer Survivor Study
癌症治疗和遗传易感性对儿童癌症长期幸存者后续肿瘤风险的贡献:圣裘德终身队列和儿童癌症幸存者研究的报告
- DOI:
10.1016/s1470-2045(25)00157-3 - 发表时间:
2025-06-01 - 期刊:
- 影响因子:35.900
- 作者:
Achal Neupane;Qi Liu;Siddhant Taneja;Jennifer French;Matthew J Ehrhardt;Tara M Brinkman;Rachel Webster;Jun J Yang;Cindy Im;Lucie M Turcotte;Joseph P Neglia;M Monica Gramatges;Rebecca M Howell;Smita Bhatia;Kirsten K Ness;Melissa M Hudson;Gregory T Armstrong;Leslie L Robison;Yutaka Yasui;Yadav Sapkota - 通讯作者:
Yadav Sapkota
Joseph P Neglia的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joseph P Neglia', 18)}}的其他基金
Bedside to Bench and Back Again: Training Pediatricians in Translational Research
床边到工作台并再次返回:培训儿科医生进行转化研究
- 批准号:
8083376 - 财政年份:2010
- 资助金额:
$ 29.62万 - 项目类别:
Bedside to Bench and Back Again: Training Pediatricians in Translational Research
床边到工作台并再次返回:培训儿科医生进行转化研究
- 批准号:
8402155 - 财政年份:2010
- 资助金额:
$ 29.62万 - 项目类别:
Bedside to Bench and Back Again: Training Pediatricians in Translational Research
床边到工作台并再次返回:培训儿科医生进行转化研究
- 批准号:
8604167 - 财政年份:2010
- 资助金额:
$ 29.62万 - 项目类别:
Bedside to Bench and Back Again: Training Pediatricians in Translational Research
床边到工作台并再次返回:培训儿科医生进行转化研究
- 批准号:
8209130 - 财政年份:2010
- 资助金额:
$ 29.62万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD LEUKEMIA
儿童白血病后的第二个恶性肿瘤
- 批准号:
3079744 - 财政年份:1987
- 资助金额:
$ 29.62万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD LEUKEMIA
儿童白血病后的第二个恶性肿瘤
- 批准号:
3079743 - 财政年份:1987
- 资助金额:
$ 29.62万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD LEUKEMIA
儿童白血病后的第二个恶性肿瘤
- 批准号:
3079741 - 财政年份:1987
- 资助金额:
$ 29.62万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD LEUKEMIA
儿童白血病后的第二个恶性肿瘤
- 批准号:
3079745 - 财政年份:1987
- 资助金额:
$ 29.62万 - 项目类别:
SECOND MALIGNANT NEOPLASMS FOLLOWING CHILDHOOD LEUKEMIA
儿童白血病后的第二个恶性肿瘤
- 批准号:
3079742 - 财政年份:1987
- 资助金额:
$ 29.62万 - 项目类别:
相似海外基金
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10308327 - 财政年份:2021
- 资助金额:
$ 29.62万 - 项目类别:
The Role of HIF1A-DNMT3A axis in AML1/ETO-Driven Acute Myelogenous Leukemia
HIF1A-DNMT3A 轴在 AML1/ETO 驱动的急性髓性白血病中的作用
- 批准号:
10312810 - 财政年份:2020
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10687861 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Dissecting the mechanistic basis of response to combined decitabine and ipilimumab following hematopoietic stem cell transplantation for relapsed acute myelogenous leukemia
剖析造血干细胞移植治疗复发性急性髓性白血病后联合地西他滨和伊匹单抗反应的机制基础
- 批准号:
430138413 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Research Fellowships
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10388497 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
9814793 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10740923 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10524124 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10197848 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别:
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
急性髓系白血病中髓系 Src 家族激酶的精确靶向
- 批准号:
10434077 - 财政年份:2019
- 资助金额:
$ 29.62万 - 项目类别: